Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Study achieves primary endpoint of radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
